GW Pharmaceuticals doubles in value after cannabis drug success in epilepsy trial

Discussion in 'Market News' started by Lily, Mar 14, 2016.

  1. Lily

    Lily Forum Member

    Aug 29, 2015
    Likes Received:
    Company now seeking talks with US regulators about approval for treatment

    An experimental cannabis-based drug from GW Pharmaceuticals has successfully treated children with a rare form of epilepsy, sending the company’s shares soaring and more than doubling its stock market value.

    GW said a clinical trial showed its Epidiolex drug had significantly reduced seizures in patients with Dravet syndrome, a type of epilesy for which there are currently no treatments approved in the US, compared to a placebo. In the trial of 120 patients, those taking Epidiolex saw a reduction of monthly convulsive seizures of 39% compared with 13% for a placebo, which GW said was highly statistically significant. The company’s chief executive Justin Gover said:

    The positive outcome of this Phase 3 trial is a significant milestone in the development of Epidiolex as a potential new treatment for patients suffering from Dravet syndrome. We are excited about the potential for Epidiolex to become the first [US Food and Drug Administration] approved treatment option specifically for Dravet syndrome patients and their families.

    Continue reading...

Share This Page

free forex signals